Ardelyx kidney drug meets main goal in mid-stage study
Feb 2 (Reuters) - Ardelyx Inc (NasdaqGM: ARDX - news) said its experimental drug significantly decreased phosphate levels in chronic kidney disease patients who were on dialysis.
The drug, being co-developed with AstraZeneca PLC (NYSE: AZN - news) , however, led to patients in the mid-stage study having a higher-than-expected rate of diarrhea. (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)